In accordance with our MOE-ASO screening data (Fig. 4A), disrupting putative SRSF1 binding sites proximal to the AD-associated SNP at the start of exon 2 did not significantly alter the level of exon 2 skipping (Fig. 5B). The gene discussed is SRSF1; the disease is Alzheimer disease.